Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Optimized Bombesin Analogues for the Imaging and Treatment of Cancer
FY 2018-19
Summary
Cancer imaging and therapy with radioactive drugs are powerful emerging methods to diagnose and treat cancer. These radiopharmaceuticals deliver radiation to cancer cells throughout the body by targeting traits that distinguish cancer cells from our healthy ones. Depending on the type of radiation, it either can destroy cancer cells or be detected by an instrument to form a precise image of the cancer in the body. One distinguishing marker in many cancer subtypes, such as prostate, breast, lung, ovarian, and colon cancers, is the abundance of gastrin-releasing peptide receptor (GRPR). Previous research has shown that bombesin (BBN) selectively binds to GRPR, and several radiopharmaceuticals based on BBN are being used clinically. However, current BBN analogues have relatively low tumour uptake, which results in poor image contrast, and they do not bind tightly enough to GRPR when carrying radiation for therapy. Our goal is to make and test new GRPR binding molecules based on BBN that bind more tightly to GRPR, thereby improving image quality and enabling use as a radiotherapeutic. I have already identified a key structural modification to include in this candidate drug that has shown to drastically improve its binding to GRPR. Furthermore, I will modify the linker, the part of the radiopharmaceutical that links the radioactivity to the targeting component, to improve tumour uptake and image contrast using established methods. These candidate drugs will be labelled with radioactivity and tested in cancer mouse models to gauge their potential as clinical imaging and therapy agents. This research will allow us to pre-clinically evaluate new potential radiopharmaceuticals that can provide earlier diagnoses and more effective therapy for multiple types of cancers.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
415328
Name
Bratanovic Ivica J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Optimized Bombesin Analogues for the Imaging and Treatment of Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bombesin; Cancer; Gastrin Releasing Peptide Receptor; Grpr; Nuclear Medicine; Positron Emission; Prostate Cancer; Radiopharmaceuticals; Radiotherapy; Targeted Therapy; Tomography
Abstract
Cancer imaging and therapy with radioactive drugs are powerful emerging methods to diagnose and treat cancer. These radiopharmaceuticals deliver radiation to cancer cells throughout the body by targeting traits that distinguish cancer cells from our healthy ones. Depending on the type of radiation, it either can destroy cancer cells or be detected by an instrument to form a precise image of the cancer in the body. One distinguishing marker in many cancer subtypes, such as prostate, breast, lung, ovarian, and colon cancers, is the abundance of gastrin-releasing peptide receptor (GRPR). Previous research has shown that bombesin (BBN) selectively binds to GRPR, and several radiopharmaceuticals based on BBN are being used clinically. However, current BBN analogues have relatively low tumour uptake, which results in poor image contrast, and they do not bind tightly enough to GRPR when carrying radiation for therapy. Our goal is to make and test new GRPR binding molecules based on BBN that bind more tightly to GRPR, thereby improving image quality and enabling use as a radiotherapeutic. I have already identified a key structural modification to include in this candidate drug that has shown to drastically improve its binding to GRPR. Furthermore, I will modify the linker, the part of the radiopharmaceutical that links the radioactivity to the targeting component, to improve tumour uptake and image contrast using established methods. These candidate drugs will be labelled with radioactivity and tested in cancer mouse models to gauge their potential as clinical imaging and therapy agents. This research will allow us to pre-clinically evaluate new potential radiopharmaceuticals that can provide earlier diagnoses and more effective therapy for multiple types of cancers.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bratanovic, Ivica J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~